IL-17 vs IL-23 vs TNF Inhibitors: 2025 Comparison for Plaque Psoriasis Treatment

Executive Brief

News Report

The News: A comparative analysis highlights the efficacy of IL-17 inhibitors over IL-23 inhibitors for plaque psoriasis.
Clinical Win: IL-17 inhibitors may provide faster skin clearance, impacting treatment decisions.
Target Specialty: Dermatology

Key Data at a Glance

PASI 75 response rate for IL-17 inhibitors: 75%
PASI 75 response rate for IL-23 inhibitors: 65%
Adverse event rate for IL-17 inhibitors: 10%
Adverse event rate for IL-23 inhibitors: 8%

A recent comparative analysis of biologics for plaque psoriasis highlights the efficacy of IL-17, IL-23, and TNF inhibitors, providing critical insights for dermatologists. This report, released in early 2025, underscores the importance of tailored treatment approaches based on individual patient profiles and disease severity.

Clinical Context

Plaque psoriasis is a chronic autoimmune condition characterized by the rapid proliferation of skin cells, leading to scaling and inflammation. The condition affects approximately 2-3% of the population globally, significantly impacting quality of life. Current treatment options include topical agents, phototherapy, and systemic therapies, including biologics that target specific pathways involved in the inflammatory process. Among these, IL-17 inhibitors (such as secukinumab and ixekizumab), IL-23 inhibitors (like guselkumab and tildrakizumab), and TNF inhibitors (including adalimumab and etanercept) have emerged as effective therapies. Despite their benefits, there remains a need for comprehensive comparisons to guide clinicians in selecting the most appropriate therapy for their patients, particularly as new data becomes available.

Key Findings

A recent study comparing IL-17 and IL-23 inhibitors found that IL-17 inhibitors significantly reduced the Psoriasis Area and Severity Index (PASI) scores by 75% in moderate-to-severe plaque psoriasis patients after 16 weeks of treatment, compared to a 65% reduction with IL-23 inhibitors [1].

The study included 1,200 patients with moderate-to-severe plaque psoriasis, randomized to receive either IL-17 or IL-23 inhibitors [1].

The primary endpoint was the percentage of patients achieving PASI 75 at 16 weeks [1].

Safety & Tolerability

Event rates for adverse effects were reported at 10% for IL-17 inhibitors versus 8% for IL-23 inhibitors, indicating a slightly higher incidence of side effects with IL-17 therapy [1].

What This Means for Clinical Practice

The findings from this comparative analysis suggest that IL-17 inhibitors may offer superior efficacy in achieving rapid skin clearance compared to IL-23 inhibitors for patients with moderate-to-severe plaque psoriasis. Clinicians should consider individual patient factors, including previous treatment responses and potential adverse effects, when selecting a biologic therapy. The slight increase in adverse events associated with IL-17 inhibitors should also be weighed against their efficacy. As the landscape of psoriasis treatment continues to evolve, staying informed on the latest comparative data will be crucial for optimizing patient outcomes.

The emergence of biosimilars in the biologics market is also noteworthy, as these agents can provide more affordable options for patients, particularly in lower-income settings [5]. This could expand access to effective therapies for a broader patient population, addressing a significant barrier in psoriasis management. Overall, the choice of therapy should be individualized, taking into account the latest evidence and patient-specific considerations.

Clinical Perspective

Workflow: Clinicians should integrate the latest comparative data into their treatment planning for plaque psoriasis.

Economics: Biosimilars may improve access to biologic therapies, particularly in resource-limited settings.

Patient Outcomes: Individualized treatment decisions based on efficacy and safety profiles will enhance patient outcomes.

Dr. Rohan Gupta, Dermatology

References

PubMed — Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis?

IL-17 vs IL-23 vs TNF Inhibitors: 2025 Comparison for Plaque Psoriasis Treatment

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

FDA Approves Icotrokinra for Plaque Psoriasis: First Oral IL-23 Antagonist

FDA Approves Icotrokinra for Moderate to Severe Plaque Psoriasis: Oral IL-23 Antagonist for Patients 12 and Older

FDA Approves Icotyde for Moderate to Severe Plaque Psoriasis: New Oral IL-23 Antagonist

Verified HCP Portal